XXXXXXXX XXXXXX V PŘENESENÉ XXXXXXXXX (XX) x. 1062/2014
xx xxx 4. xxxxx 2014,
xxxxxxxx se xxxxxxxxxx xxxxxxxx systematického xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx obsažených x xxxxxxxxxx xxxxxxxxxxx, xxxxx xxxx xxxxxxx x xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012
(Xxxx x xxxxxxxx pro XXX)
XXXXXXXX XXXXXX,
x xxxxxxx na Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,
x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. května 2012 x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx a xxxxxx xxxxxxxxx (1), a zejména xx čl. 89 xxxx. 1 první xxxxxxxxxxx xxxxxxxxx nařízení,
xxxxxxxx x těmto xxxxxxx:
(1) |
Xxxxxxxx Xxxxxx (XX) x. 1451/2007 (2) xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxx xxxxxxxx xxxxxxxxxxx biocidních xxxxxxxx xxxxx (xxxx xxx „xxxxxxx přezkumu“), xxxxx xxx xxxxxxx x xxxxxxx x xx. 16 odst. 2 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx 98/8/XX (3). Xxxxxxx xxxx xxxxxxxx xxxx zrušena x xxxxxxxxx xxxxxxxxx (XX) x. 528/2012, měla xx xxx xxxxxxxxx pravidla xxx pokračování xxxxxxxx xxxxxxxx xxxxxxxxxxxx ustanovením xxxxxxxxx xxxxxxxx. |
(2) |
Xx důležité xxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx, které xxxxx xxx xxxxxxxx na trh x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx 89 nařízení (XX) č. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx. Xxxx xx xxxx být x x případě xxxxxxxxx účinné xxxxx x typu xxxxxxxxx, xxxxx jsou hodnoceny x xxxxxxxx xxxxxxxx. |
(3) |
Xxxxx xxxxxxxxx využíval xxxxxxxx xxx xxxxxxxxx x xxxxxx xxxxx xxxxxx 6 xxxxxxxx (XX) č. 1451/2007, xxx xxxxxxxxxx se xx xxx xxxxxxx xxx xxxxxxxxx x xxxxxx xxxxxxx x xx. 2 odst. 5 xxxx. x) xxxxxxxx (XX) x. 528/2012, xxxx xx xxx xxxxxx xxxxx, xxxxx xxxxxxxx, xxxxxxxxx x xxxxxxxx přezkumu pro xxxxxxxxx typ xxxxxxxxx. X xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxx xxxxxxxx na trh x xxxxxxxxx xxxxxxxx xx xx xxxxxxxx xxxxxxxxx hodnocení. Xxxxxx xxxxxxxxxxx xxxxxxxxxx xx měl vymezit, xxxxx přípravky tohoto xxxxxxxxxx xxxxxxx. Totéž xx xxxx platit x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx vyplynulo x xxxx xxxxxxxx xxxx xxxxxxxxx v nařízení (XX) č. 528/2012 xxxxxx xxxxxxxx uvedené xx xxxxxxxx 98/8/ES nebo xx xxxxx xxxxxxxxxx xxxxxxxxxxx Komise xxxxxxxx x xxxxxxx x xx. 3 odst. 3 xxxxxxxx (XX) x. 528/2012, xxxxxxxxxxx (například xxxxxxxxxxx xx xxxx C-420/10 (4)) xxxx závaznými xxxxxx Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xxxxx se následně xxxxxxx. |
(4) |
Xxxxx biocidní přípravek xxxxxxxx xxxxxxx látku, xxxxx již xxxx xxxxxxxx xx programu xxxxxxxx, x xxxx xxxxx sestává xxxx xx z ní xxxxxx, xxxxx xxxxxxxx xx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx v členském xxxxx xxxxxxxx, mělo xx xxx x xxxxx xxxxxxxx xxxxx použití x xxxxxxxx xx xxx xxxxxxxx xx xxxx xxxxxxxxxxxx, za určitých xxxxxxxx x xx omezenou xxxx. |
(5) |
X xxxxx jednotnosti x xxxxxxxxxxxx by xxx xxx xxxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx ve všech xxxxxxxxxx částech totožný x xxxxxxxx stanoveným xxx xxxxxxx předložené xxxxx článku 7 xxxxxxxx (XX) x. 528/2012 xxxx xxxxx xxxxxxxxxxx nařízení Xxxxxx (XX) x. 88/2014 (5). |
(6) |
Pro xxxxx, xxxxx xxxxxxx xxxxxxxx xxxxxxxxx nebo xxxxxxxx xxx náhradu, xx měl xxxxxxxxx xxxxxxxxx xxxxx předložit xxxxxxxx návrh xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxx xxxxx xx. 37 xxxx. 1 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (ES) x. 1272/2008 (6), xxxxx xxx o xxxxxxxxx vlastnosti xxxxxxxxxx xxxxx, a zároveň xx xxxx xxx xxxxxxxxx xxxxx členského xxxxx xxxxxxxxx návrh xxxxxxxx xx jiných xxxx xxxxx sledovaných vlastností. Xxxxxxxxx příslušný xxxxx xx xxx xxxx xxxxxxxxxxx xxxxxxxx x xxxxxxx xxxxx, xxxxx xx xxxxxxxxx kritéria xxx xxxxx xxxxxxxxxxxx, xxxxxxxxxxxxxxx či toxické, nebo xxxxx, xxxxx by xxxxx xxx xxxxxxxxxx xx xxxxx x xxxxxxxxxxx xxxxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx. |
(7) |
Xxx xxxx xxxxxxxxx, xx xxxxxxx xxxxxxxx xxxx xxxxxxxx xx xxxxxxxx data xxxxxxxxx x xx. 89 xxxx. 1 nařízení (XX) č. 528/2012, xxxx xx xx hodnocení xxxxxx na xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx, x xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxx stanovených x xxxxxxxx (XX) č. 1451/2007 xxxx x xxxxx nařízení. Xxxxx xxxx xx xx xxxx xxxxxxxx xxxxxx xxxxx xxx xxxxxxxxx xxxxxxxxx, xxxxxxx xx se xxxx xxxx x úvahu xxxxxxx, xx žádosti xx mohly xxx xxxxxxxxx xxxx než xxx před xxxxxxxxx xxxxxx lhůt. |
(8) |
Xxxxxxx zařazení xx xxxxxxx I xxxxxxxxx 7 xxxxxxxx (XX) č. 528/2012 xxxxx xxxxxx xxxxxxxxx žádné xxxxxxxxx xx xxxxx. Xx proto xxxxxx x xxxx xxxx xxxxxx žádosti x xxxxxxxx xx uvedené xxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 nebo 6. |
(9) |
Xxx xxxxxx xx xx. 90 xxxx. 2 xxxxxxxx (EU) x. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx xxxxxxx x xxxxxx 10 xxxxxxxxx xxxxxxxx xx xxxx být xxxxxxxxxx xxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxx xxxxxxxxx. Xx proto xxxxxx xxxxx xxxxx xxxxxxxxx xxxx xxxxxxxx xx xxxxx xxxxxxxxxxx účinných xxxxx. |
(10) |
Xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx by měl xxx xxxxxxx xx xx xxxxxxxx dohodě xxxxxxxx ke stávajícímu xxxxxxxxxxx xxxx xxx xxxxxxxx xx xxxxxxxxxxx, xx kvůli xxxx xxxxxxx xx xxxxxxxx xxxxxxxxx x xxxxxx xxxxxxxxx xxxxxxxx x xxxxxx, xxxxxxx jinak xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxx. |
(11) |
Xxxxxxx xx xxxxx v programu xxxxxxxx dobrovolná, mělo xx xxx xxxxxxxxxx xxxxxxxx od xx xxxxxxxxx. Xxxxx k xxxx xxxxx, xxxx xx mít potenciální xxxxxxxxx xxxxxxx převzít xxxxxxx, nebylo-li xxxx xxxxxxxx využito xxx xxxxxx, xxxxx xxx xxxxxxx ke xxxxxxxx xxxxxxxx xxxxxxxx, x xxxxxxxx-xx agentura xxx xxxxxxxx na svém xxxxxxxxxx. |
(12) |
Xxxxx se xxx xxxxxxxxx účinné látky xxxxx, xx xxxxxxxx oficiálně xxxxxxxx xx xxxxxxxx přezkumu xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx, x x xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxx xxxxxxxx oficiálně xxxxxxxx xxxxx, xxxx xx xxx xxxxx tuto xxxxx v průběhu xxxxxxxxx xxxxx definovat a povolit xxxxx xxxxxx, aby xxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx látky. |
(13) |
Některé xxxxx xxxxxxxx xx xxxxxxxx přezkumu nejsou x době xxxxxxx xxxxxx xxxxxxxx podporovány xxxxxx účastníkem. Xxxxx xx xxxx určitých xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 xxxx. 4 xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxxx nelze xxxxxxxx, xxxxx xxx xxxx xxxxxxxx xxxxxxxxx. X xxxxxxxxx xxxxx x xxxxxxxxxxxxx by xxxx xxx osoby xxxxxxx xxxxxxx účast, protože xxxxx xx xxxx xxxxx x xxxxxxxxxxxxx xxxxxx xxx z xxxxxxxx xxxxxxxx vyloučeny. |
(14) |
Aby xxxx xxxxxxxxx, xx xxxxx xxxxx nezůstane x xxxxxxxx xxxxxxxxxxx ani xx něj nebude xxxxxxxx, xxxx by xxxxxxxx xxxx xxxxxxxxxxx, xxxx xx xxxxxxxx xxxxx, xxxxx xxxxx xxxxxx hodnocena, v xxxxxxxx xxxx její xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx údajů x xx, |
XXXXXXX XXXX XXXXXXXX:
XXXXXXXX 1
PŘEDMĚT X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx pravidla pro xxxxxxxxx xxxxxxxxxx programu xxxxxxxxxxxxxx přezkumu všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx v článku 89 xxxxxxxx (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Xxx účely xxxxxx xxxxxxxx xx xxxxxxx xxxx definice:
a) |
„rozhodnutím x xxxxxxxxxxx“ se xxxxxx xxxxxxxxxx neschválit xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxx xx. 9 xxxx. 1 xxxx. x) nařízení (XX) x. 528/2012 xxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx uvedeného nařízení, xxxx xxxxxxxxx nezařadit xx xxxxxxx X xxxx XX xxxxxxxx 98/8/XX; |
b) |
„xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx xx xxxxxxxx přezkumu“ xx xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx XX, xxxxx xxxxxxx xxxx xxxxxxxx:
|
x) |
„xxxxxxxxxx“ xx xxxxxx osoba, xxxxx xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxx do programu xxxxxxxx nebo předložila xxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 17 xxxx. 5 xxxxxx nařízení, xxxx xxxxxx xxxxxx xxxx tato xxxxxx xxxx xxxxxxxx xxxxxxxxxx; |
x) |
„xxxxxxxxxx xxxxxxxxxx orgánem“ xx xxxxxx xxxxxxxxx orgán xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 2
XXXXXX XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxx X xxxxxxxx (EU) x. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx či xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) č. 528/2012 může xxxxx pouze xxxxxxxx, x jehož oznámení xxxxx xxxxxxxx x xxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxx čl. 17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx xxxxxx xxxx xxxxxxxx do přílohy X&xxxx;xxxxxxxx (XX) č. 528/2012, xxxx xx xxxxx pouze xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxxxxx v odstavci 1 xx podávají xxxxxxxx xx&xxxx;xxxx xxx xx xxxxxxxxxx x&xxxx;xxxxxxx x požadavky xxxxx xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Přijetí xxxxxxx
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 564/2013 (7) x zamítne xxxxxx, xxxxx xxxxxxxx nezaplatí xxxxxxxx xx lhůtě 30 xxx. X xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx i xxxxxxxxx xxxxxxxxx orgán.
2. Po xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx (EU) x. 564/2013 přijme xxxxxxxx xxxxxx x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx příslušný xxxxx, xxxxxxx xxxxx xxxxx xxxxxxx žádosti x xxxx xxxxxxxxx identifikační xxx.
3. Proti xxxxxxxxxxx agentury xxxxx xxxxxxxx 1 tohoto xxxxxx xxx podat xxxxxxx prostředek x xxxxxxx x xxxxxxx 77 xxxxxxxx (EU) x. 528/2012.
4. Hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx xx. 80 xxxx. 2 nařízení (XX) x. 528/2012 xx 30 dnů xxxx, co xxxxxxxx xxxxxxx xxxxxx, a xxxxxxx xxxxxx, pokud xxxxxxxx xxxxxxxxx poplatek xx xxxxx 30 xxx. O xxxx xxxxxxxxxxx informuje xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Xxxxxxxxx žádostí x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) č. 528/2012
1. Xxxxx xxxxxxxx xxxxxx xxxxx čl. 4 xxxx. 2 xxxxxx x xxxxxxxxx nebo xxxxxxxx xx xxxxxxxxx 6 přílohy X xxxxxxxx (EU) x. 528/2012, xxxxx xxxxxxxx údaje xxxxxxxxxx x xxxxxxx x xx. 6 xxxx. 1 a 2 xxxxxxxxx nařízení, x xxx xxxxxxxx poplatek podle xx. 4 xxxx. 4, xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxx do 30 dnů xx zaplacení xxxxxxxx.
2. Pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx od účastníka dokumentaci xxxxx nařízení (ES) x. 1451/2007, xxxxx ta xxxxx xxxxxx xxxxxx xxxx úplná xxxxx xxxxxx 13 uvedeného xxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X xxxxxxxxx xxxxxxxxx x xxxxxxxxxx 1 x 2 xxxxxxxxx xxxxxxxxx xxxxx neprovádí xxxxxxxxx kvality ani xxxxxxxxxxxx xxxxxxxxxxxx údajů xxxx xxxxxxxxxx.
4. Xxxxx hodnotící xxxxxxxxx xxxxx xxxxxx, xx xxxxxx je xxxxxxx, xxxxx xxxxxxxxxxx, xxxx doplňující xxxxxxxxx xxxx x xxxxxxxxx xxxxxxx nutné, a x xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx. Tato xxxxx xxxxx nepřesáhne 90 dnů.
Xxxxxxxx-xx xxxxxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx 2, xxxxxxx xxxxxx xx 30 xxx od xxxxxxxx xxxxxxxxxxxx informací.
Jestliže xxxxxxxx požadované xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, xxxxxxxxx příslušný xxxxx xxxxxx xxxxxxx x informuje x xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxx. V xxxxxx případech xx xxxxx xxxxxxxx zaplacené x xxxxxxx x xx. 80 xxxx. 1 x 2 xxxxxxxx (XX) x. 528/2012.
Xxx xxxxxxxxx žádosti xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx příslušné xxxxxx x xxxxx xxxxx xxxxxx xxxxxxxxx.
Xxxxxx 6
Xxxxxxxxx xxxxxxx
1. Tento xxxxxx xx použije, xxxxx xxxxx xxxxxxx x xxxxxx podmínek:
x) |
je-li xxxxxx xxxxxxxxx podle xxxxxx 5; |
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx uznal xxxxxxxxxxx xxxx úplnou xxxxx xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, xxx xxxxx xxxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx podle xx. 14 odst. 4 uvedeného xxxxxxxx; |
x) |
xxxxx agentura xxxxxxx xxxxxx x xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 přílohy X xxxxxxxx (XX) x. 528/2012 xxxxx xx. 4 xxxx. 2 x xxx zaplacen xxxxxxxx xxxxx čl. 4 xxxx. 4. |
2. Hodnotící xxxxxxxxx xxxxx zhodnotí xxxxxx xxxxx xxxxxx 4 x 5 xxxxxxxx (XX) x. 528/2012 x případně xxx xxxxxxx návrhy xx xxxxxx požadavků xx xxxxx předložené x souladu x xx. 6 xxxx. 3 xxxxxxxxx xxxxxxxx x xxxxx hodnotící xxxxxx a xxxxxx xxxxx xxxxxxxxx xxxxxxxx.
3. Xxxxx xxxxxxx xxxxxxxxx látky x xxxx přípravků xxxxxxxxx několik účastníků, xxxxxxxxx xxxxxxxxx příslušný xxxxx xxxxx jednu xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx a závěry zašle x jedné z těchto xxxx, xxxxx toho, xx nastane později:
x) |
365 xxx po xxxxxxxxx xxxxxxxxx xxxxxxxx v odst. 1 xxxx. x), xxxxxx úplnosti xxxxxxxx v odst. 1 písm. b) xxxx zaplacení poplatku xxxxxxxxx x xxxx. 1 xxxx. x) x dotyčné xxxxxxxxx xxxxx a typu xxxxxxxxx; |
x) |
ve xxxxx stanovené v příloze XXX. |
4. Xxxx xxx, xxx xxxxxxxxx příslušný xxxxx xxxxxxxx své xxxxxx xxxxxxxx, xxxxxx xxxxxxxxxxx xxxxx xx 30 xxx x xxxxxxxxx xxxxxx x k xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx způsobem xxxxxxxx x závěrečné xxxx xxxxx xxxxxxxxx.
5. Xxxxx xx xxxxx, xx jsou x xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxx, x xxxxxxxxx x tom xxxxxxxx.
Xxxxx 365 dnů xxxxxxx v odstavci 3 xx přeruší xx dobu ode xxx xxxxxxxx xxxxxxxxx xx xxx obdržení xxxxxxxxx. Xxxxx to xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxx nebo xxxxxxxxxxx xxxxxxxxxx, přerušení xxxxxxxxxx následující xxxxx:
a) |
365 xxx x xxxxxxx, xx xx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, které xxxxxx xxxxxx v xxxxx xxxxxxxx 98/8/XX xxxx v rámci xxxxxxx xxxxxxxxxxx xxx uplatňování xxxxxxx xxxxxxxx; |
x) |
180 xxx xx xxxxx xxxxxxxxx xxxxxxxxx. |
6. Xxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxx, xx existují xxxxx ohledně xxxxxx xxxx nebo zvířat xxxx xxxxxxxxx prostředí vyplývající x xxxxxxxxxxxxx xxxxxx plynoucích x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx účinné xxxxx, xxx xxxxx zdokumentuje x xxxxxxx s požadavky xxxxxxxxxxx xxxxx xxxxxx II xxxx 3 přílohy XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 (8) a zahrne xx xx svých xxxxxx.
7. X xxxxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx x xxxxxxxxxx při xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx odstavce 3:
x) |
předloží xxxxx xxxxxxxx xxxxx xx. 37 xxxx. 1 xxxxxxxx (XX) č. 1272/2008, xxxxxxxx xx domnívá, že je xxxxxxx xxxxx x xxxxxxxx xxxxxxxxx x xx. 36 xxxx. 1 xxxxxxxxx nařízení, ale xxxx xxxxxxxx xxxxxx x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
b) |
konzultuje x xxxxxxxxx, xxxxx se xxxxxxx, xx xxxxx x xxxxxxxx xx. 5 xxxx. 1 xxxx. x) xxxx x) xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxx xx. 10 odst. 1 xxxx. x) xxxxxxxxx xxxxxxxx xxxx xxxxxxx, xxx xxxxxx xxxxxxxx xxxxxx x xxxxxxx XXX nařízení (XX) x. 1907/2006 xxxx v seznamu xxxxxxxx x xx. 59 xxxx. 1 xxxxxxxxx xxxxxxxx. |
Xxxxxx 7
Xxxxxxxxxx xxxxxxxx
1. Tento xxxxxx xx xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx podmínek:
x) |
xxxxx hodnotící xxxxxxxxx orgán xxxxxxxxx xxxxxxxxx xxxxxx podle xx. 6 xxxx. 2 x xxxxxxxx xxxxxxxxx xxxxx xxxx provedl xxxxxxxxxx xxxxx xx. 6 xxxx. 7; |
x) |
pokud xxxx předložena Komisi xxxxxx příslušného orgánu xxxxx čl. 14 xxxx. 4 xxxxxxxx (XX) č. 1451/2007, xxx xxxxxxxxx zprávu xxxxx xxxxxxxxxxxx Stálý xxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xx. 15 xxxx. 4 uvedeného nařízení. |
2. Xx xxxxxxx zprávy agentura xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) č. 528/2012, xxxxxxxx xxxxxx, s ohledem xx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx x xxxxx x xxxxxx xxxx, podle xxxx, xx xxxxxxx později:
a) |
do xxx měsíců xx xxxxxxx xxxxxx; |
x) |
ve xxxxx xxxxxxxxx x xxxxxxx XXX. |
Xxxxxxxx xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 xxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné látky, xxxxx xx xxxx xxxxxxxx
1. Xxx xxxxxxxx svého xxxxxxxxxx podle čl. 7 xxxx. 2 xxxxxxxx xxxxxxx, xxx xxxxxx látka xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, x xxxx xxxxxx xxxxx xx xxxx stanovisku.
2. Aniž xxxx xxxxxxx xxxxxx 66 x 67 xxxxxxxx (XX) x. 528/2012, xxxxx než xxxxxxxx xxxxxxxx své xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx o možných xxxxxxx, xxxxx xx xxxx xxxxxxxx, xxxxx xxxxxxxxx 60 xxx; x xxxx době xxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx příslušné xxxxxxxxx xxxxxx informací x xxxxxxxxxx xxxxxxxxx. Xxxxxxxx obdržené xxxxxxxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxx xxxxxxxx xxxxx xxxxxxxxxx.
3. Pokud xx xxxxxx látka xxxxxxxxx x xxxxxxx jedno x xxxxxxxx stanovených x xx. 10 xxxx. 1 xxxxxxxx (EU) x. 528/2012, xxxx xxx xxxxxxxx xx látku, xxxxx xx xx xxxxxxxx, x xxxxxxxx přijatém x xxxxxxx x xx. 89 xxxx. 1 xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Xxxxxx
Xx xxxxxxxx stanoviska agentury xxxxx xx. 7 xxxx. 2 Xxxxxx xxx zbytečného xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx pro xxxxxxx xxxxx čl. 89 xxxx. 1, xxxx xxxxxxxx podle xx. 28 xxxx. 1 xxxxxxxx (XX) x. 528/2012.
KAPITOLA 3
XXXXX XXXXX XXXXXXXX PŘEZKUMU
Článek 10
Xxxxxxxxx xxxx xxxxxxxxx účastníků xx xxxxxxxx xxxxxx
1.&xxxx;&xxxx;&xxxx;Xxxx xxxxxxxxx je xxxxx xx xxxxxxxx xxxxxx xxxx stávajícím xxxxxxxxxx x xxxxxxxxxxxx účastníkem xxxxxxx xxxx sdílet xx předpokladu, že xx potenciální xxxxxxxx xxxxx xxxxxxxxx se xx xxxxxxx xxxxx xxxxxxxxxx nebo uvedené xxxxxxxxxx účastníkem.
2. Oznámení xxx xxxxx xxxxxx článku xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx účastník xxxxxxxxxxxxxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx uvedeného x xxxxxx 71 xxxxxxxx (XX) x. 528/2012 (dále xxx „xxxxxxxx“) x&xxxx;xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxxx.
3.&xxxx;&xxxx;&xxxx;Xx xxxxxxxx oznámení splňujícího xxxxxxxxx xxxxx xxxxxxxx 2 agentura aktualizuje xxxxxxxxx x&xxxx;xxxxxxxxx týkající xx xxxxxxxxxx xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx xxxx xx xxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx článku, xx xxx účely xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 xxxxxxxxxx xx xxxxx, xxxxx xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx x přístupu x xxxxxxxxxxx.
Xxxxxx 11
Xxxxxxxxxx xxxxxxxxx
1. Xx xx xx xx, xx xxxxxxxx xxxxxxxxx x účasti xx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxxxxx xxxxxxxx, x xxxxxx xxxxxxxxx:
x) |
xxxxx informoval xxxxxxxx xxxx hodnotící příslušný xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxx záměru xxxxxxxxx; |
x) |
xxxxx xxxxxxxxxxx žádost xx lhůtě xxxxxxx x xx. 3 xxxx. 2; |
x) |
xxxxx xxxx xxxxxx byla zamítnuta xxxxx xx. 4 odst. 1, xx. 4 odst. 4 xxxx xx. 5 xxxx. 4; |
d) |
pokud xxxxxxxxxxx xxxxxxxxxx informace xx xxxxxxx uvedených v čl. 6 xxxx. 5; |
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx nebo xxxxxxxx. |
2. Xxxxxxxxxx xx xxxxxxxx xx xxxxxxxxx včas, xxxxx x němu xxxxxxx xx xxxx, kdy xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx žadateli zprávu xxxxxxxxxxx orgánu xxxxx xx. 6 xxxx. 4 xxxxxx xxxxxxxx.
Xxxxxx 12
Xxxxxxxx xxxxxxxx xxxxxxxxxx
1. Xxxxx xx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx orgán, xxx xxxxxx agentura, xxxxxxxxx xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx xx x xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, aktualizuje xxxxxxxxx x xxxxxxxxx xxxxxxxx se xxxxxxxxxx účastníka.
3. Xxxxx x xxxxxxxx xxxxxxxx včas xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxx xxxx role xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxx převzata, xxxxxxxxx x tom xxxxxxxx xxxxxxxxxxxxxxx rejstříku Xxxxxx.
Xxxxxx 13
Xxxx xxxxxxxx xxxxxxxxx xxxxx
1. Xxxxx hodnocení xxxxxxxxx xxxxxx látky xxxxxxxx vyvodit xxxxxx xxxxxxxx xx látky, xxx xxxx uvedeny x xxxxxxx XX, hodnotící xxxxxxxxx xxxxx xx xxxxxxxxxx x dotyčným xxxxxxxxxx xxxxxxx xxxxx identitu xxxxx. Xxxxxxxxx příslušný xxxxx x xxx informuje xxxxxxxx.
2. Xxxxxxxx v rejstříku xxxxxxxxxxx xxxxxxxxx týkající xx xxxxxxxx látky.
Xxxxxx 14
Převzetí xxxx xxxxxxxxx
1. Xxxxxxxx zveřejní xxxxxxxxx xxxxx x xxxxxxxx xxxx xxxxxxxxx xxx xxxxxxxxx látky x xxxx xxxxxxxxx, pokud xxxxxxx xxxxx x xxxxxx xxxxxxx:
a) |
xxxxx xxxxxxx účastníci podporující xxxxx kombinaci xxxxx x xxxx přípravku xxxx xxxxxxxxxx xxxxx xxxxxx 11 x xxxxxx xxxx xxxxxxxxx xxx danou xxxxxxxxx xxxxxx předtím převzata; |
x) |
na základě xxxx xxxxxxxx xxxxx xxxxxx 13; x xxxxx xxxxxxx xx xxxxx týká xxxxx té xxxxx, xx xxxxxx xx xxxxxxxx xxxxxxxxx identita x xxxxxxx XX, xxx xxxxxxx xxxx xxxxxxxx xxxxx. |
2. Xx xxxxxxxx xxxxxx xxx xxx zveřejnění xxxxx xxxxxxxx 1 xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxx xxxxxx 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx xxxxxx nařízení x xxxxxxxx xxxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx xx xxxxx 2 přílohy II podle xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx látky x typu xxxxxxxxx xxxxxxxxx xxx zařazení xx programu xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx do xxxxxxx xxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xx xxxxxx na xxx, xxxxxxx xx xxxxxxxxx xxxxxx xxxxx, jež xxxx xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxx xxxxx xxx xxxxxxxxx x xxxx xxxxxxxx xx xxxxxxx X xxxxxxxxx xxxxxxxx, xxxx xxxxx xxxxxxxx xxxx xx x xx xxxxxx, xx xxxxxxx xxxxx xxxxxxxxx pro zařazení xx xxxxxxxx přezkumu pro xxxxxxxxx typ xxxxxxxxx xx xxxxxxx xxxxxxxxx x xxxxxx xxxxxx:
x) |
xxxxx xxxxxxxxx xxxxxxx xx xxx xx xxxxxxxxx xx pokyny xxxx xxxxxxx xxxxxxxxxx xxxxxx Xxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 26 směrnice 98/8/XX xxxx xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, xxxxx na základě xxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxx uvedené pokyny xx doporučení x xxxxxxxxxxx, že výrobek xxx xxxxx x xxxxxxxxxx xxxxxxxx 98/8/XX xxxx nařízení (XX) x. 528/2012, xxxx xx xxx xxxxxxxxx xxx xxxxxxxxx jedním x xxxxxxxxx, xxx xxxxx byla xxxxxx xxxxx xxxxxxxx, x xxxxx xxxx xxxxxxx xxxxxx či xxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx přijatém xxxxx xx. 3 odst. 3 xxxxxxxx (EU) x. 528/2012 xxxx x xxxxxx, závazných xxxxxxxx xxxxxxxxxxxx Komisí; |
x) |
xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx a krmiva xxxxxxxxx x xxxxxx 6 nařízení (XX) č. 1451/2007; |
c) |
xxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxx (XX) x. 528/2012 x xxxxxxxxx xxxx xxxxxxxxx, xxx xxxx bylo xxxxx xxxxxxxx 98/8/XX, x xxxxxxxx xxxxx xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxx zařazenou xx xxxxxxxx xxxxxxxx xxx xxxxxxx xxx přípravku, ale xxxxxx xxx xxxx. |
Xxxxxx 16
Xxxxxxxxxx x xxxxx xx xxxxxxxx
1. Prohlášení x xxxxx oznámit xxxxx, xxxxx je způsobilá xxx xxxxxxxx do programu xxxxxxxx xxxxx xxxxxx 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx osoba, xxx xx xxxxx xxxxxxx kombinaci xxxxx x xxxx přípravku, jednomu x xxxxxxxxxxxxx xxxxxxxx:
x) |
Komisi xxxxxxxxxx xxxxxxx měsíců xx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxxxxxx x xx. 15 písm. a); |
x) |
xxxxxxxx nejpozději 30. xxxxx 2015 x xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
x) |
Xxxxxx xxxxxxxxxx 30. října 2015 v případech xxxxxxxxx v xx. 15 xxxx. x). |
2. Xxxxxxxxxx musí obsahovat xxxxxxxxxx xxxxxxxxx xxxxx x xxxx přípravku. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) xxxx xxxxxxxxxx xxxxxxxxx opodstatněné xxxxxxxxxx, x xxxx xxxxxxx, xx xxxx splněny xxxxxxx podmínky x xxx xxxxxxx.
3. Xxxxx bylo xxxxxxxxxx xxxxxxx v případě xxxxxxxx x xx. 15 písm. x) xxxx c) x Xxxxxx xxxxxxx xx xxxxxxxxxx x xxxxxxxxx xxxxx x xxxxxx, xx xxxxxxxx 6 xxxx xxxxxxxxxx, x xxxxxxxx, že xxxx splněny xxxxxxxx xxx oznámení xxxxxxx x xx. 15 xxxx. a), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx xxxx xxxxxxxxxx xxxxxxx x xxxxxxx uvedeném x xx. 15 xxxx. x) xxxx pokud Xxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 3, xxxxxxxx xxxxxxxx xxxx informaci elektronickými xxxxxxxxxx s uvedením xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. Pro xxxxx xxxxxx xxxxxxxx se xxxxxxxxxx podle xx. 3x xxxx. 3 xxxxxxx xxxxxxxxxxx xxxxxxxx (ES) x. 1451/2007 xxxxxxxx xx zveřejnění xxxxx xxxxxx xxxxxxxx.
5. Xxxxxxxxx xxxxx, xxxxx má xxxxx xxxxxxx xxxxxxxxx xxxxx a xxxx xxxxxxxxx, xxx xxxx xxxxxx xxxxx xxxxxx 17 xx xxxxx xxxxxx xxx xxx xxxxxxxxxx xxxxx xxxxxxxx 4.
6. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) x x) xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx považuje xx xxxxxxxxx xxxxxxxxxx a není xxxxxxxxx x xxxxxxx xxxxxxxx, xxxxx xxxx xxxxxxx xxxx xxxxxxxx:
x) |
xxxxxxxxx xxxxxx xxxxx xx xxx xxxxxxxx xx xxxxxxxx xxxxxxxx; |
x) |
xxxxxxxxxxx xxxxxxxxxx hodnotícímu xxxxxxxxx xxxxx pro xxxxxxxxxx xxxxxxx látku xxx obsahuje všechny xxxxx, xxxxx xxxx xxxxxxxx xxx hodnocení xxxx xxxxxxxxx; |
c) |
účastník, který xxxxxxxxx xxxxxxxx dokumentaci, xxxxx, xx xx xxxxx o xxxxxxx xxxx xxxxxxxxx látky x xxxx přípravku. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Xxxxxxxx xxxxx xx. 14 xxxx. 2 x 3 xxxx xx. 16 odst. 5 xx xxxxxxxxxxx agentuře xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx xx xxxxxxx XXXXXX. Xxxx xxxxxxxxx xxxxx uvedené v xxxxxxx X.
3. Xxxxx xxxx x xxxxxxx XX xxx xxxxxxxx xxxxxxx látku xxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx xxxxxxxxxxx agenturu x xxxxx xxx vybraného xxxxxxxxxxx xxxxxx, xxxxx xx xxxxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, a poskytne písemné xxxxxxxxx xxxxxxxxxxx, xx xxxxxxxxx xxxxx souhlasí x xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx xxxxxxxx xxxxxxxx x xxx uvědomí xxxxxxxx Komisi x xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx podle xxxxxxxx (XX) č. 564/2013. Jestliže xxxxxxxxxxx neuhradí poplatky xx 30 dnů xx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxx x uvědomí x xxx xxxxxxxxxxxx x Xxxxxx.
5. Po xxxxxxxx xxxxxxxx agentura do 30 xxx ověří, xxx xxxxxxxx xxxxxxxx xxxxxxxxxx uvedeným x xxxxxxxx 2. Pokud xxxxxxxx těmto požadavkům xxxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxxxxxxx lhůtu x xxxxx 30 dnů, xxx xxx xxxxxxxx xxxxxxx xxxx xxxxxxx. Xx xxxxxxxx xxxx 30xxxxx xxxxx xxxxxxxx xx 30 dnů xxx prohlásí, xx xxxxxxxx xxxxxxxx požadavkům xxxxxxxx 2, xxxx xxxxxxxx zamítne, a xxx rozhodnutí sdělí xxxxxxxxxxxx a Xxxxxx.
6. V xxxxxxx x xxxxxxx 77 xxxxxxxx (XX) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 4 nebo 5 xxxxx xxxxxxx xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx 5:
x) |
x xxxxxxx, xx xxxx xxxxxxxx xxxxxxxxxx podle xx. 14 odst. 2 xxxx 3, agentura neprodleně xxxxxxxxxxx xxxxxxxxx v xxxxxxxxx týkající se xxxxxxxxxx účastníka x xxxxxxxx xxxxxxxx xxxxx; |
x) |
x xxxxxxx, xx xxxxxxxx xxxx xxxxxxxxxx xxxxx čl. 16 xxxx. 5, xxxxxxxx xxxxxxxxxx xxxxxxxxx Xxxxxx, xx xxxxxxxxxx bylo xxxxxxxx. |
Xxxxxx 18
Xxxxxxxx xx xxxxxxxx přezkumu
Pokud je xxxxxxxxx látky a typu xxxxxxxxx xxxxxxxxxx xx xxxxxxxxx v souladu s čl. 16 xxxx. 6 xxxx pokud xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxxx požadavků x xxxxxxx s čl. 17 xxxx. 7 xxxx. x), xxxxxx Xxxxxx kombinaci xxxxx x xxxx xxxxxxxxx do xxxxxxxx přezkumu.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxx xxxxxx ve lhůtě stanovené x xx. 16 odst. 5 xxxxxxxx xxxxx xxxxxxxx xxxx xxxxx xxxx xxxxxxxx xxxxxxx xx zmíněném xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx podle xx. 17 xxxx. 4 xxxx 5, xxxxxxxx o tom xxxxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxx a zveřejní xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Xxxxxx x látkách, které xxxxxx xxxxxx podporovány x xxxxx xxxxxxxx xxxxxxxx
Xxxxxx xxxxxxxx xxxxx xxxxxxxxxx o xxxxxxxxxxx xxxxx xx. 89 odst. 1 xxxxxxx pododstavce nařízení (XX) č. 528/2012 x xxxxxx xxxxxxxxx:
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx o včasném xxxxxxxxxx xxxxxxxxx xxxxx xx. 12 xxxx. 3 xxxxxx xxxxxxxx; |
x) |
xxxxx xxxxx xxxxx xxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxxxxx x xx. 14 odst. 2 nebo 3 xxxxxx xxxxxxxx xxxx pokud bylo xxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5; |
x) |
pokud xxxx xxxxxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 tohoto xxxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 5 tohoto xxxxxxxx, xxx identita xxxxx x xxxxxxxx xxxxxxxx pouze xxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX tohoto xxxxxxxx. |
X xxxxxxx xxxxxxxx v prvním pododstavci xxxx. x) se xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx, xx xxxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, avšak xxxxxx xxxxxxxx nebo jakékoli xxxxxxxxxx x xxxxxxxxx.
KAPITOLA 4
XXXXXXXXX XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx xxx xxxxx xxxxxxx v článku 15
1. Členský xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx nebo xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx přípravku, xxxxx xxxxxxx xx xxxxxxxxx xxxxxx látky uvedené x čl. 15 xxxx. x) x x), xxxx látku xxxxxxxx xxxx x xx vzniká. V xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx přípravek xxxxxx xxxxxxx xx&xxxx;xxx s účinkem xx&xxxx;24 xxxxxx po xxxx xxxxxx xxxxxx xxxxxxxx v platnost; |
b) |
stávající xxxxxx xxxxxxxxxx přípravku mohou xxx xxxx využívány xx&xxxx;30 xxxxxx xx xxx vstupu tohoto xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx xxxxxxxxx účinné xxxxx xxxxxxx x xx. 15 xxxx. x), xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. V xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx nadále xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 měsíců xx xx z dále xxxxxxxxx xxxxxxxx, xxxxx xxxxxxx xxxxxxx:
|
b) |
stávající xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx být xxxx xxxxxxxxx xx&xxxx;30 xxxxxx xx té x xxxx xxxxxxxxx xxxxxxxx, xxxxx nastane xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx stát může xxxxxxxxxx x&xxxx;xxxxxxxxxxx svého xxxxxxxxxxx xxxxxxx nebo xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx přípravku, xxxxx sestává xx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxx agenturou xxxxx xx. 16 xxxx. 4 pro xxxxxxxxx xxx xxxxxxx, xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. X xxxxxx xxxxxxxxx:
x) |
xxxxx xxx biocidní přípravek xxxxxx dodáván na trh x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx měsíců xx xxxx, kdy xxxxxxxx provedla elektronické xxxxxxxxxx xxxxx článku 19 x |
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále využívány xx&xxxx;xxxxxxxx xxxxxx xx xxxx xxxxxxxxx zveřejnění. |
Xxxxxx 22
Nezbytná xxxxxxx
1. Aniž xx dotčen xx. 55 xxxx. 1 nařízení (XX) x. 528/2012, do osmnácti xxxxxx xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxx, xxxxx xxxxxxx stát xxxxxxxx tuto xxxxxxxxx xxxxxxx xxxxx xx xxxxxxxxx x xxxxxx xxxxxxxxx x xx. 5 xxxx. 2 xxxxxx xxxxxxxxxxx xxxx. x) xxxx x) xxxxxxxx (EU) x. 528/2012, xxxxx členský xxxx xxxx xxxxxxxxx Xxxxxx odůvodněnou žádost x xxxxxxxx xx xx. 89 odst. 2 xxxxxxx xxxxxxxxxxx uvedeného xxxxxxxx.
2. Xxxxxxxx členský xxxx xxxxxxxx xxxxxxxxxxx xxxxxx xxxxxxxx prostřednictvím xxxxxxxxx. Xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxx stát xxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx zveřejní žádost xxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx xxxxx xxxx xxxx xxxxx xxxxx xxxxx xxxxxxxxxx xx xxxxx 60 xxx po xxxxxxxxxx.
4. Xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxx Komise xxxxxxx xxxxxxxx od čl. 89 xxxx. 2 druhého xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012, xxxxx umožní xxxxxx xxxxxxxx xxxxxxxxx, xxx xxxxxxxxx x xxxx xxxxx, xxxxxxxx ji xxxx x ní xxxxxxxx, xx xxx xxxxxxxxxx členského státu x xxxxxxxx je x xxxxx xxxxxxxx xxxxx x xxxxxxx x xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx x x xxxxxxxx podmínek xxxxxxxx 5 x xxxxxxxxx xxxxxxx xxxxxxxx uložených Komisí.
5. Xxxxxxx xxxx, jemuž je xxxxxxxx xxxxxxxx:
a) |
zajistí, xx xxxxx xxxxxxxxx bude omezeno xx xxxxxx xxxxxxx x xxxxxxx xxxx, xxx xxxx xxxxxx xxxxxxxx xxxxxxxx 1; |
x) |
xxxxxx xxxxxx opatření xx xxxxxxxx xxxxx, aby xxxxxxxx xxxxxxxxxxxx expozice xxxxxxx, xxxxxx nebo xxxxxxxxx xxxxxxxxx; |
x) |
xxxxxxx, xxx xx hledala alternativní xxxxxx xxxx xxx xxxx xxxx před xxxxxxxxx xxxxxxxxx odchylky xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxxx xxxxx x xxxxxxx xxxxxxx 7 nařízení (XX) č. 528/2012. |
KAPITOLA 5
XXXXXXXXX XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx xx nařízení (XX) x. 1451/2007.
Xxxxxx xx xxxxxxx xxxxxxxx xx xxxxxxxx xx xxxxxx xx xxxx xxxxxxxx.
Xxxxxx 24
Xxxxx v xxxxxxxx
Xxxx xxxxxxxx vstupuje x platnost dvacátým xxxx xx xxxxxxxxx x Xxxxxxx věstníku Xxxxxxxx xxxx.
Xxxx xxxxxxxx xx xxxxxxx v celém xxxxxxx a přímo xxxxxxxxxx ve všech xxxxxxxxx státech.
V Bruselu xxx 4. srpna 2014.
Xx Xxxxxx
xxxxxxxx
Xxxx Xxxxxx XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. L 167, 27.6.2012, x. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Komise (XX) x. 1451/2007 xx xxx 4. prosince 2007 x xxxxx xxxxx desetiletého xxxxxxxxxx xxxxxxxx xxxxxxxxx x xx. 16 odst. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx 98/8/XX x uvádění xxxxxxxxxx xxxxxxxxx xx xxx (Xx. věst. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx 98/8/ES xx dne 16. xxxxx 1998 o xxxxxxx xxxxxxxxxx přípravků xx xxx (Xx. xxxx. X 123, 24.4.1998, s. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Soudního xxxxx (xxxxxxx xxxxxx) xx xxx 1. xxxxxx 2012 (xxxxxx x xxxxxxxxxx x xxxxxxxxx xxxxxx: Xxxxxxxxxxx Xxxxxxx – Xxxxxxx) – Xöxx XxxX xxxxx Xxxxx GmbH (xxxxxxx xxxxxxxxxx přípravků xx xxx – xxxxxxxx 98/8/XX – xx. 2 xxxx. 1 xxxx. x) – xxxxx „biocidní xxxxxxxxx“ – xxxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx škodlivých xxxxxxxxx, aniž xx xxxx, odpuzuje xxxx xxxxxxxxxxx), X-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) x.&xxxx;88/2014 xx xxx 31.&xxxx;xxxxx 2014, xxxxxx xx stanoví xxxxxx xxx xxxxx xxxxxxx I nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 o dodávání biocidních xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Xx. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx x xxxxx, x xxxxx x xxxxxxx směrnic 67/548/EHS x 1999/45/XX x x xxxxx nařízení (XX) x. 1907/2006 (Xx. xxxx. L 353, 31.12.2008, x. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) x.&xxxx;564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx xxxxx xxxxxxxx Xxxxxxxxxx parlamentu x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx přípravků xx trh x&xxxx;xxxxxx xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, x. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1907/2006 ze xxx 18. xxxxxxxx 2006 x xxxxxxxxxx, xxxxxxxxx, povolování x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Evropské xxxxxxxx xxx xxxxxxxx xxxxx, o změně xxxxxxxx 1999/45/XX a x xxxxxxx nařízení Xxxx (XXX) č. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Komise 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/XX (Úř. věst. X 396, 30.12.2006, x. 1).
XXXXXXX X
Xxxxxxxxx požadované xxx xxxxxxxx xxxxx xxxxxx 17
Oznámení podle xxxxxx 17 xxxxxxxx xxxx informace:
1) |
xxxxx, xx xxxxx xx xxxxxxxxx xxxxxxx xxxxxx xx xxxxxx xx. 3 xxxx. 1 xxxx. x) nařízení (XX) č. 528/2012; |
2) |
údaje x xxxx/xxxxxx přípravku, na xxxxx/x se xxxxxxxx xxxxxxxx; |
3) |
xxxxxxxxx o všech xxxxxxxx, xxxxx xxxx xxxxxx xxx xxxxx žádosti x xxxxxxxxx či zařazení xx xxxxxxx X xxxxxxxx (XX) x. 528/2012, jakož x xxxxxxxxx xxxxx xxxxxx dokončení; |
4) |
xxxxxxxxx xxxxxxx v oddílech
|
5) |
xxxxx xxxx xxxx oznámení xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x), xxxxx, xx xxxxx xxxx xx xxxx xxxx účinná xxxxx xxxxxxxxxx přípravku xxxxxxxxxxx xx xxxxxxxxxxx typu xxxxxxxxx x xxx xxxxxxxx xxxx xxxxxxxxxx rozhodnutí xxxx pokynů xxxxxxxxx xx zmíněném xxxxxxx. |
XXXXXXX XX
KOMBINACE XXXXX X XXXX XXXXXXXXX XXXXXXXX XX XXXXXXXX PŘEZKUMU XXX 4. SRPNA 2014
XXXX 1
Xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx podporované xx xxx 4. xxxxx 2014, s výjimkou xxxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxx, které xxxx výslovně xxxxxxx x xxxxxxxxx 1017 x 1019.
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx XX |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1 |
xxxxxxxxxxx |
DE |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
6 |
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
40 |
propan-2-ol |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx xxxxxxxxxx |
NL |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
propan-1-ol |
DE |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
N |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
kyselina xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx kyselina |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-isopropenyl-8,9-dimethoxy-1,2,6,6a,12,12a-hexahydrochromeno[3,4-b]furo[2,3-h]chromen-6-on (xxxxxxx) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
85 |
symklosen |
UK |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
113 |
cinnamaldehyd/3-fenylprop-2-enal (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (xxxxxxxxxxxxx) |
FI |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
154 |
chlorofen |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
172 |
cetylpyridinium-chlorid/1-hexadecylpyridin-1-ium-chlorid |
UK |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx uhličitý |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
180 |
(natrium-kakodylát) – natrium-dimethylarsinát |
PT |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (sodná xxx xxxxxxxxxxxxxxx – xxxxxxxxx X) – (N-chlor-4-methylbenzen-1-sulfonamid |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
xxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
195 |
natrium-bifenyl-2-olát |
ES |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (thiabendazol) |
ES |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
235 |
xxxxxx |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
239 |
karbamonitril |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
253 |
tetrahydro-3,5-dimethyl-1,3,5-thiadiazin-2-thion (xxxxxxx) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
279 |
N-[(dichlorfluormethyl)sulfanyl]-N′,N′-dimethyl-N-(4-methylfenyl)sulfonamid (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (dichlofluanid) |
UK |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
289 |
thiokyanatan xxxxx |
XX |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
315 |
xxxxx-2-xx-xxxxxxx |
HU |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
monolinuron |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
X-(3-xxxxxxxxxxx)-X-xxxxxxxxxxxxx-1,3-xxxxxx (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
ES |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (MES) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
xxxxxxxxx |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (EGForm)) |
PL |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
365 |
pyridin-2-thiol-1-oxid, xxxxx xxx (pyrithion xxxxx) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
PL |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
382 |
1,3,4,6-xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxxxxxxxxx[4,5-x]xxxxxxxx-2,5-xxxx (XXXX) |
XX |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
397 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
401 |
xxxxxxx |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
403 |
měď |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
405 |
oxid xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
NL |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
432 |
xxxxxxxx sodný |
XX |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
439 |
xxxxxxx xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (EDHO) |
XX |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
450 |
xxxxxxxx xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx vápenatý |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
457 |
xxxxx |
IT |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
458 |
síran xxxxxx |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
473 |
pyrethriny x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
491 |
oxid xxxxxxxxxx |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
494 |
2,2-xxxxxx-2-xxxxxxxxxxxx (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
515 |
xxxxxx amonný |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
522 |
xxxx-1-xxx-1λ5-xxxxxxx-2-xxxxxxx |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
524 |
dodecylguanidin-monohydrochlorid |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
529 |
xxxxxxxxxxxxxxx |
XX |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
UK |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
534 |
bis(1-hydroxypyridin-2(1H)-thionato-O,S)měďnatý xxxxxxx (xxxxxxxxx mědi) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
550 |
5,5′-bis(4-chlorfenyl)-1,1′-(hexan-1,6-diyl)bis(biguanid)-bis(d-glukonát) (CHDG) |
PT |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
XX |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (prallethrin) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (sorbát xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (HPT) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
571 |
2-xxxxxxxxxxxxxxxxxxxxxxxxx-3-xx (OIT) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
577 |
xxxxxxxx(xxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
ES |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
578 |
N2-terc-butyl-N4-cyklopropyl-6-(methylsulfanyl)-1,3,5-triazin-2,4-diamin (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (BCDMH/bromchlordimethylhydantoin) |
NL |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
590 |
3-(4-xxxxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx/xxxxxxxxxxx |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
597 |
1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]imidazol (xxxxxxxx) |
DE |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
961 |
xxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
608 |
dimethyl(tetradecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
609 |
xxx- a xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (citriodiol) |
UK |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
614 |
(RS)-α-kyano-3-fenoxybenzyl-(1RS)-cis,trans-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropanekarboxylát (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
IE |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
619 |
3-xxxxxxx-2-xx-1-xx-X-xxxxxxxxxxxxx (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx kokosového xxxxx (XXXXX/XXXX) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
648 |
4,5-dichlor-2-oktylisothiazol-3(2H)-on (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (DCOIT)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (triflumuron) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (cyromazin) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (cyfluthrin) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
671 |
alkyl(C12-16)dimethylbenzylammoniumchlorid (ADBAC/BKC (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
MT |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
bis(peroxosíran)-bis(síran) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
xxxxxxx, Xxxxxxxxxxx xxxxxx, výtažek |
DE |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
725 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxx (ADEBAC (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
731 |
xxxxxxxxx stračkolistá, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxx |
ES |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
744 |
xxxxxxxxx zvrhlá, Xxxxxxxxx xxxxxxx, xxxxxxx/xxxxxxxxxxx xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
XX |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
779 |
xxxxxxx xxxxxxxx xxxxxxxxx kyseliny x X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (xxxxxxxxxxxxx) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
792 |
xxxxxxx tetrachlordekaoxidu (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
XX |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (xxxxxxxx) |
DK |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
797 |
1-((X)-3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxxxxxxxxx (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-methylprop-1-en-1-yl)cyklopropan- 1-karboxylát (xxxx xxxxxxxxxxxxx) (imiprothrin) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
790 |
5-chlor-2-(4-chlorfenoxy)fenol (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (chlothianidin) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
952 |
Bacillus xxxxxxxxxx 2362, xxxx XXXX-1743 |
XX |
xxxxxxxxxxxxxxx |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx subsp. xxxxxxxxxxx, xxxx XX3X |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
957 |
Bacillus xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-chlor-2-methylisothiazol-3(2H)-on (Xxxxxx 247-500-7) a 2-methylisothiazol-3(2H)-on (Xxxxxx 220-239-6), xxxx (3:1) (xxxx XXXX/XXX) |
XX |
směs |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
939 |
xxxxxxx xxxxx (xxxxxxxx xxxxxx xxxxxxxx chlorné a xxxxxxxxx sodného xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx xxxxxxxx |
XX |
xxxx xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx zeolit |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
931 |
xxxxxxxxxxxxxxxxxxxxxxx, X-X12-14(xx sudým číslem), xxxxxxxx xxxxxx x xxxxxxxxxxxx kyselinou (Xxxxxxxx 20) |
XX |
xxxx relevantní |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx xxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx s xxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
459 |
reakční xxxx xxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxx |
SE |
není x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
777 |
xxxxxxx produkty 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx k dispozici |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
824 |
stříbrno-zinečnatý zeolit |
SE |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
není x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx oxidu xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxx xx nanoúrovni) |
XX |
není k dispozici |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (jako xxxxxxxxxxxx tvořený xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
831 |
xxxxxxxxx |
FR |
přípravek xx xxxxxxx rostlin |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (xxxx 4 izomerů 1X xxxxx, 1R: 1R xxxxx, 1S: 1X xxx, 1X: 1X xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
DE |
přípravek na xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (xxxxxxxxxxx) |
BE |
xxxxxxxxx xx ochranu rostlin |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
835 |
esfenvalerát/(S)-(3-fenoxyfenyl)kyanmethyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát (xxxxxxxxxxxx) |
XX |
xxxxxxxxx na xxxxxxx xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
BE |
xxxxxxxxx xx xxxxxxx xxxxxxx |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (chlorfenapyr) |
PT |
xxxxxxxxx xx xxxxxxx rostlin |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
859 |
polymer X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) s (xxxxxxxxxxx)xxxxxxxx (XXXXXX 203-439-8)/polymerní xxxxxxxxx xxxxxxx xxxxxx (XX Xxxxxxx) |
XX |
polymer |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
863 |
poly(biguanid-1,5-diylhexan-1,6-diyl) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
FR |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
XX |
xxxxxxx |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
872 |
N-didecyl-N-dipolyethoxyammonium-borát/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx xxxxxx) |
EL |
polymer |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx xxxxxx látky x xxxx přípravku nepodporované xx xxx 4. xxxxx 2014
Xxxx xxxx xxxx přílohy xxxxxxxx
— |
kombinace xxxxx x xxxx xxxxxxxxx xxxxxxx v tabulce xxxx, xxxxxx případných xxxxxxxxx, |
— |
jakékoli xxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx v tabulce v části 1, xxxxx xxxx, xxxxx xxxx uvedeny x xxxxxxx, x |
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx 4. xxxxx 2014, x xxxxxxxx těch, xxxxx xxxx xxxxxxxx schváleny. |
Xxxxxxxxx xxxxx a typu přípravku x xxxxxxxxxxxxx zařazené xx xxxx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx 20, xxxxxxxx xxxxx xxxxx nepodá xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx v platnost podle xx. 14 xxxx. 3 nebo xxxxx xx takové xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5.
Xxxxx xxxxxxx |
Xxxxx látky |
Xxxxxxx xxxx zpravodaj |
Číslo XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (nově definovaný xxxxx xxxxxxx 152) |
NL |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
benzyl(dimethyl)oktadecylamonium-chlorid (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx amorfní |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
SE |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
benzyldimethyl(oktadec-9-en-1-yl)amonium-chlorid (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
637 |
alkyl(benzyl)dimethylamonium-chloridy (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (alkyl xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx hydrogenovaných xxxxxxxx xxxxxxx loje) (xxx xxxxxxx 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
dialkyl(C6-C12)dimethylamonium-chloridy (xxx položka 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
dialkyl(C8-C18)dimetylamonium-chloridy (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx margosy xxxx xxx x jader xxxxxxxx Azadirachta xxxxxx xxxxxxxxxxx xxxxx x xxxx zpracovaný xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx xxxxxxxxxx xxxxx položky 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx xxxxxxx xxxxxxxx-xxxxxxx, xxxxxxxx-xxxxxxxxx x xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X6-X18) xxxxxxxx a xxxxxxxxxx, xxxxxxxx od xxxxxxxx xxxxxxx xxxx, xxxxxxxxxx oleje x xxxxxxxx xxxxx) (DDAC) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X8-X18) nasycené x nenasycené, xxxxxxxx xx mastných xxxxxxx xxxx, xxxxxxxxxx xxxxx x sójového xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxxxxx) (alkyly (C8-C22) xxxxxxxx a nenasycené, xxxxxxxx od mastných xxxxxxx xxxx, xxxxxxxxxx xxxxx x xxxxxxxx xxxxx) (XXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (d-fenothrin) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
1001 |
alkyl(C12-C16)benzyl(dimethyl)amonium-chloridy (xxxx než látka xxxxxxxxx xxx položku 671) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
1002 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx(xxxx xxx xxxxx xxxxxxxxx xxx položku 667) |
XX |
není xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- chloridy (xxxx xxx xxxxx xxxxxxxxx xxx položku 725) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1005 |
alkyl(C12-C14)benzyl(dimethyl)amonium-chloridy (xxxx než látka xxxxxxxxx xxx xxxxxxx 724) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1006 |
xxxxxxxxxxxxxx xxxx xxxxxxxxxx stříbro, xxxxx, xxxxxx a xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1009 |
xxxxxxx(X8-X10)xxxxxxxxxxxxxx-xxxxxxxx (xxxx xxx xxxxx spadající xxx xxxxxxx 673) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 635) |
XX |
xxxx relevantní |
xxxx relevantní |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, stříbrný x xxxxxxxxx komplex/stříbrno-zinečnatý zeolit |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx technický) |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
Xxxx xxxxxxxxx |
Xxxxx pro xxxxxxxxxx xxxxxxxxx zprávy xxxxx čl. 6 odst. 3 xxxx. x) |
Xxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 7 odst. 2 xxxx. x) |
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
1 x 2 |
31.12.2018 |
31.3.2019 |
6 x 13 |
31.12.2019 |
31.3.2020 |
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |